Patients undergoing cancer treatments must often contend with the potentially life-threatening consequences of cytotoxic chemotherapy. Newer cancer treatments increasingly involve the use of targeted agents that inhibit epidermal growth factor receptor (EGFR). Although targeted agents are not associated with the toxicities typical of traditional antineoplastic agents, a wide range of cutaneous reactions and other bothersome adverse effects are seen in a majority of patients.
Many EGFR inhibitors are given orally and present new challenges for oncology nurses, pharmacists, and physicians. Evidence-based practice for the unique side effects associated with EGFR inhibitors is still evolving.